Recombinant Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, His tag, 100µg

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Cynomolgus / Rhesus macaque OX40, His Tag (OX0-C5220) is expressed from human 293 cells (HEK293). It contains AA Lys 28 - Ala 214 (Accession # XP_001090870.1). In the region Lys 28 - Ala 214, the AA sequence of Cynomolgus and Rhesus macaque OX40 are homologus.
Predicted N-terminus: Lys 28

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.1 kDa. The protein migrates as 33-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the Cynomolgus / Rhesus Macaque TNFRSF4 / OX40 / CD134 by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

References

(1) "E3 Ubiquitin Ligase March1 Facilitates OX40L Expression in Allergen-Stimulated Dendritic Cells Through Mediating the Ubiquitination of HDAC11"
Zhang, Sun, Guo et al
J Asthma Allergy (2021) 14, 955-966
(2) "OX40L blockade cellular nanovesicles for autoimmune diseases therapy"
Fu, Wang, Liu et al
J Control Release (2021) 337, 557-570
(3) "A Combination of Cowpea Mosaic Virus and Immune Checkpoint Therapy Synergistically Improves Therapeutic Efficacy in Three Tumor Models"
Wang, Steinmetz
Adv Funct Mater (2020) 30 (27)

Showing 1-3 of 1705 papers.
Please refer to product data sheet.